HuGE Literature Finder
Records
1
-
30
Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN). International journal of environmental research and public health 2021 Jul 18 (14): . Zulkeflee Razan Hayati, Zulkafli Zefarina, Johan Muhammad Farid, Husin Azlan, Islam Md Asiful, Hassan Rosli |
Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era. Journal of clinical medicine 2021 Mar 10 (5): . Lee Jong-Mi, Lee Howon, Eom Ki-Seong, Lee Sung-Eun, Kim Myungshin, Kim Yongg |
Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis. International journal of hematology 2021 Jan . Morishita Soji, Ochiai Tomonori, Misawa Kyohei, Osaga Satoshi, Inano Tadaaki, Fukuda Yasutaka, Edahiro Yoko, Ohsaka Akimichi, Araki Marito, Komatsu Nor |
Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms. British journal of haematology 2020 Sep . Garcia-Gisbert Nieves, Fernández-Ibarrondo Lierni, Fernández-Rodríguez Concepcion, Gibert Joan, Andrade-Campos Marcio, Arenillas Leonor, Camacho Laura, Angona Anna, Longarón Raquel, Salar Antonio, Calvo Xavier, Besses Carlos, Bellosillo Beatr |
Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. Hematology, transfusion and cell therapy 2019 Oct . Porto-Soares Moysés Antonio, de Oliveira Rafael Daltro, Cortopassi Gabriel Macedo, Machado-Neto João Agostinho, Palma Leonardo Carvalho, Figueiredo-Pontes Lorena Lobo |
TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients. International journal of hematology 2019 Sep . Matsuguma Masafumi, Yujiri Toshiaki, Yamamoto Kaoru, Kajimura Yasuko, Tokunaga Yoshihiro, Tanaka Mayumi, Tanaka Yoshinori, Nakamura Yukinori, Tanizawa Yuk |
Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. European journal of haematology 2019 Apr . Edahiro Yoko, Araki Marito, Inano Tadaaki, Ito Masafumi, Morishita Soji, Misawa Kyohei, Fukuda Yasutaka, Imai Misa, Ohsaka Akimichi, Komatsu Nor |
Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis. Experimental oncology 2019 Mar 41 (1): 53-56. Poluben L, Bryke Ch R, Hsu Y, Shumeiko O, Neumerzhitska L, Klimuk B, Rybchenko L, Klymenko S, Balk S P, Fraenkel P |
The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. American journal of hematology 2019 Mar 94 (3): 299-305. Tefferi Ayalew, Lasho Terra L, Mudireddy Mythri, Finke Christy M, Hanson Curtis A, Ketterling Rhett P, Gangat Naseema, Pardanani Anime |
Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. American journal of hematology 2018 Oct . Poluben Larysa, Puligandla Maneka, Neuberg Donna, Bryke Christine R, Hsu Yahsuan, Shumeiko Oleksandr, Yuan Xin, Voznesensky Olga, Pihan German, Adam Miriam, Fraenkel Ernest, Rasnic Roni, Linial Michal, Klymenko Sergiy, Balk Steven P, Fraenkel Paula |
[Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases]. Zhongguo shi yan xue ye xue za zhi 2018 Aug 26 (4): 1122-1128. Li Zhen-Ling, Gao Li, Zhang Hui, Zhang Chun-Xia, Chen Yan-Rong, Huang Fan-Zhou, Gong Ming, Gao Ya-Yue, Tang Yin, Ma Yi-G |
GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. Annals of laboratory medicine 2018 Jul 38 (4): 296-305. Yang Naery, Park Sholhui, Cho Min Sun, Lee Miae, Hong Ki Sook, Mun Yeung Chul, Seong Chu Myong, Huh Hee Jin, Huh Jungw |
Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. International journal of hematology 2018 Feb . Misawa Kyohei, Yasuda Hajime, Araki Marito, Ochiai Tomonori, Morishita Soji, Shirane Shuichi, Edahiro Yoko, Gotoh Akihiko, Ohsaka Akimichi, Komatsu Nor |
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leukemia research 2018 Jan 65 42-48. Gángó Ambrus, Mózes Réka, Boha Zsófia, Kajtár Béla, Timár Botond, Király Péter Attila, Kiss Richárd, Fésüs Viktória, Nagy Noémi, Demeter Judit, Körösmezey Gábor, Borbényi Zita, Marton Imelda, Sz?ke Anita, Masszi Tamás, Farkas Péter, Várkonyi Judit, Plander Márk, Pósfai Éva, Egyed Miklós, Pál Katalin, Radványi Gáspár, Hamed Aryan, Csomor Judit, Matolcsy András, Alpár Donát, Bödör Csa |
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center. Neoplasma 2018 65 (2): 296-303. Palova M, Szotkowski T, Hlusi A, Indrak K, Navratilova J, Divoka M, Papajik |
[Detection of ASXL1 Mutation and CALR Mutation Coexistance in Patients with Ph Negative Myeloproliferative Neoplasm and Its Clinical Gignificance]. Zhongguo shi yan xue ye xue za zhi 2017 Dec 25 (6): 1738-1743. Chen Mei-Yu, Shen Hong-Jie, Chao Hong-Ying, Zhou Min, Lu Xu-Zhang, Zhang Xiu-Wen, Liu Jie, Jiang Nai-Ke, Wang Qi |
The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis. Journal of clinical pathology 2017 Dec . Kuo Ming-Chung, Lin Tung-Huei, Sun Chien-Feng, Lin Tung-Liang, Wu Jin-Hou, Wang Po-Nan, Huang Ying-Jung, Chang Hung, Huang Ting-Yu, Shih Lee-Yu |
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. American journal of hematology 2017 Nov . Tefferi Ayalew, Nicolosi Maura, Mudireddy Mythri, Szuber Natasha, Finke Christy M, Lasho Terra L, Hanson Curtis A, Ketterling Rhett P, Pardanani Animesh, Gangat Naseema, Mannarelli Carmela, Fanelli Tiziana, Guglielmelli Paola, Vannucchi Alessandro |
CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands) 2017 Oct 1-4. Ojeda Mara Jorgelina, Bragós Irma Margarita, Calvo Karina Lucrecia, Williams Gladis Marcela, Carbonell María Magdalena, Pratti Arianna Flav |
MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. American journal of hematology 2017 Oct . Trifa Adrian P, B?nescu Claudia, Bojan Anca S, Voina Cristian M, Popa ?tefana, Vi?an Simona, Ciubean Alina D, Tripon Florin, Dima Delia, Popov Viola M, Vesa ?tefan C, Andreescu Mihaela, Török-Vistai Tünde, Mih?il? Romeo G, Berbec Nicoleta, Macarie Ioan, Coli?? Andrei, Iordache Maria, C?tan? Alina C, Farca? Marius F, Tomuleasa Ciprian, Vasile Kinga, Truic? Cristina, Todinc? Adriana, Pop-Muntean Lavinia, Manolache Raluca, Bumbea Horia, Vl?d?reanu Ana-Maria, Gaman Mihaela, Ciufu Cristina M, Popp Radu |
Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leukemia research 2017 Jun 60 18-23. Barosi Giovanni, Massa Margherita, Campanelli Rita, Fois Gabriela, Catarsi Paolo, Viarengo Gianluca, Villani Laura, Poletto Valentina, Bosoni Tiziana, Magrini Umberto, Gale Robert P, Rosti Vittor |
Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Medical oncology (Northwood, London, England) 2017 May 34 (5): 83. Chang Yu-Cheng, Lin Huan-Chau, Chiang Yi-Hao, Chen Caleb Gon-Shen, Huang Ling, Wang Wei-Ting, Cheng Chun-Chia, Lin Johnson, Chang Yi-Fang, Chang Ming-Chih, Hsieh Ruey-Kuen, Chen Shu-Jen, Lim Ken-Hong, Kuo Yuan-Y |
Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients. Hematology (Amsterdam, Netherlands) 2017 Apr 1-8. Limsuwanachot N, Rerkamnuaychoke B, Chuncharunee S, Pauwilai T, Singdong R, Rujirachaivej P, Chareonsirisuthigul T, Siriboonpiputtana |
[Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance]. Zhongguo shi yan xue ye xue za zhi 2017 Feb 25 (1): 151-156. Tang Qin, Zhang Xiu-Wen, Xia Lei, Jiang Nai- |
The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. American journal of hematology 2017 Feb . Mudireddy Mythri, Barraco Daniela, Hanson Curtis A, Pardanani Animesh, Gangat Naseema, Tefferi Ayal |
Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. Genes, chromosomes & cancer 2016 Dec . Luque Paz Damien, Chauveau Aurélie, Boyer Françoise, Buors Caroline, Samaison Laura, Cottin Laurane, Seegers Valérie, Férec Claude, Le Maréchal Cédric, Gueguen Paul, Lippert Eric, Ianotto Jean-Christophe, Ugo Valér |
Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. British journal of haematology 2016 Nov 175 (3): 419-426. Delic Sabit, Rose Dominic, Kern Wolfgang, Nadarajah Niroshan, Haferlach Claudia, Haferlach Torsten, Meggendorfer Man |
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica 2016 Sep . Rozovski Uri, Verstovsek Srdan, Manshouri Taghi, Dembitz Vilma, Bozinovic Ksenija, Newberry Kate, Zhang Ying, Bove Joseph E, Pierce Sherry, Kantarjian Hagop, Estrov Ze |
[Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2016 Jul 37 (7): 576-80. Xu Z F, Li B, Liu J Q, Li Y, Ai X F, Zhang P H, Qin T J, Zhang Y, Wang J Y, Xu J Q, Zhang H L, Fang L W, Pan L J, Hu N B, Qu S Q, Xiao Z |
CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion. Current research in translational medicine 0 65 (1): 15-19. Smaili W, Doubaj Y, Laarabi F Z, Lyahyai J, Kerbout M, Mikdame M, Sefiani |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 09, 2022
- Content source: